IN THE CLAIMS:

Please amend the claims as set forth in the Listing of Claims which replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound having the formula (I):



(I)

wherein

X is selected from the radicals $-NR_1-$ and $-CHR_1-$;

Y is independently selected from O and S;

Z is independently selected from a C_{1-7} straight or C_{4-8} branched alkylene chain, a C_{2-7} alkenylene chain and a part of a C_{3-8} cycloalkyl or C_{5-8} cyc[[k]]loalkenyl ring structure;

Ar is an aryl group selected from aromatic carbocyclic ring systems, five- or six-membered heteroaromatic ring systems and bicyclic heteroaromatic ring systems;

R_1, R_2 and R_3 are independently selected from a group of substituents (a)-(d) consisting of:

(a) H;

(b) C_{1-6} straight or C_{4-8} branched chain alkyl;

(c) C_{3-8} cycloalkyl or C_{5-8} cyc[[k]]loalkenyl; and

(d) C_{2-6} alkenyl or alkynyl;

wherein the substituents (b)-(d) optionally have at least one substituent independently selected from a group (e)-(i) consisting of:

(e) Ar, O-Ar or S-Ar;

(f) OH, O-alkyl or S-alkyl, where alkyl is selected from the substituents (b)-(c);

(g) NR_4R_5, where R_4 and R_5 are independently selected from the substituents (a)-(d) or optionally together form a nitrogen containing ring structure comprising from 2 to 5 carbon atoms;

(h) NH-C(O)-alkyl, C(O)-alkyl, O-C(O)-alkyl or S-C(O)-alkyl, where alkyl is selected from the substituents (b)-(c); and

(i) F, Cl or Br;

R_6 is selected from a group consisting of Ar and the substituents (a)-(c), where (b) and (c) are optionally substituted with at least one of the substituents (e)-(i);
Ar optionally has at least one substituent independently selected from the substituents (b)-(i); and
tautomers, solvates and pharmaceutically acceptable salts of said compound.

2. (Currently amended) The[[A]] compound according to claim 1, wherein X is a radical $-NR_1-$.

3. (Currently amended) The[[A]] compound according to claim 2, wherein R_1 is H.

4. (Currently amended) The[[A]] compound according to ~~any one of~~ claim[[s]] 1[[-3]], wherein Y is O.

5. (Currently amended) The[[A]] compound according to ~~any one of~~ claim[[s]] 1[[-4]], wherein Ar is selected from phenyl and naphthyl.

6. (Currently amended) The[[A]] compound according to ~~any one of~~ claim[[s]] 1[[-5]], wherein Z is selected from $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$ and *trans*-2-cyclohexylene.

7. (Currently amended) The[[A]] compound according to ~~any one of~~ claim[[s]] 1[[-6]], wherein R_6 is selected from isopropyl, cyclopentyl, cyclohexyl, phenyl, 4-*n*-butylphenyl, 4-isopropylphenyl and 2-naphthyl.

8. (Currently amended) The[[A]] compound according to ~~any one of~~ claim[[s]] 1[[-7]], wherein R_2 and R_3 are independently selected from H and 4-chlorobenzyl.

9. (Currently amended) The[[A]] compound according to ~~any one of~~ claim[[s]] 1[[-8]], wherein the compound is selected from a group consisting of:
4-[3-phenyl-1-(6-phenylhexyl)ureido]butyramide;
4-[1-(4-butylbenzyl)-3-phenylureido]butyramide;
4-[1-(4-isopropylbenzyl)-3-phenylureido]butyramide;
4-[1-(4-methylpentyl)-3-phenylureido]butyramide;
N-(4-chlorobenzyl)-4-[1-(3-cyclohexylpropyl)-3-phenylureido]butyramide;
trans-2-[1-(3-cyclohexylpropyl)-3-phenylureido]cyclohexanecarboxamide;
4-[1-(3-cyclohexylpropyl)-3-naphthalen-2-yl-ureido]butyramide;
4-[1-(2-naphthalen-2-yl-ethyl)-3-phenylureido]butyramide;
4-[1-(2-cyclohexylethyl)-3-phenylureido]butyramide;
4-(1-phenethyl-3-phenylureido)butyramide;
4-(1-benzyl-3-phenylureido)butyramide;
4-[1-(3-cyclopentylpropyl)-3-phenylureido]butyramide;
4-[3-phenyl-1-(5-phenylpentyl)ureido]butyramide; and
4-[1-(3-cyclohexylpropyl)-3-phenylureido]butyramide.

10. (Currently amended) The[[A]] compound according to claim 1, wherein X is a radical $-CHR_1-$.

11. (Currently amended) The[[A]] compound according to claim 10, wherein said radical $-CHR_1-$ is selected from $-CH_2-$ and (*R*)-$CH(CH_3)$-.

12. (Currently amended) The[[A]] compound according to ~~any one of~~ claim[[s]] 10[[-11]], wherein Y is O; Ar is selected from phenyl and naphthyl; Z is selected from $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$ and *trans*-2-cyclohexylene; R_6 is selected from isopropyl, cyclopentyl, cyclohexyl, phenyl, 4-*n*-butylphenyl, 4-isopropylphenyl and 2-naphthyl; and R_2 and R_3 are independently selected from H and 4-chlorobenzyl~~Y, Z, Ar, R_2, R_3 and R_6 are as defined in claims 4-8~~.

13. (Currently amended) The[[A]] compound according to ~~any one of~~ claim[[s]] 10[[-12]], wherein the compound is selected from the[[a]] group consisting of:
(*R*)-4-[(3-cyclohexylpropyl)-(2-phenylpropionyl)amino]butyramide;
4-[(3-cyclohexylpropyl)-(2-naphthalen-2-yl-acetyl)amino]butyramide; and
8-[(3-cyclohexylpropyl)-(2-naphthalen-2-yl-acetyl)amino]octanamide.

14. (Currently amended) The[[A]] compound according to ~~any one of~~ claim[[s]] 1[[-13]] for use as a pharmaceutical.

15. (Currently amended) A pharmaceutical composition comprising the[[a]] compound according to ~~any one of~~ claim[[s]] 1[[13]] as active ingredient in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

16. (Currently amended) Use of the[[a]] compound according to ~~any one of~~ claim[[s]] 1[[13]] for the manufacture of a medicament for treatment of pain and disorders related thereto.

17. (Currently amended) A method for treatment of pain and disorders related thereto, wherein said method comprises administering to an animal, including human, patient of a therapeutically effective amount of the[[a]] compound according to ~~any one of~~ claim[[s]] 1[[-13]].